Literature DB >> 12045717

Pathogenesis of multiple sclerosis: an update on immunology.

Bernhard Hemmer1, Sabine Cepok, Stefan Nessler, Norbert Sommer.   

Abstract

Multiple sclerosis is characterized by demyelination and chronic inflammation of the central nervous system. Extensive studies in the animal model experimental autoimmune encephalomyelitis have suggested that multiple sclerosis is an autoimmune disorder mediated by myelin-specific CD4 T cells secreting T helper type 1 cytokines and tumor necrosis factor alpha. This concept has been widely used to develop new experimental therapies. However, recent findings in both experimental autoimmune encephalomyelitis and multiple sclerosis question a simple CD4 T helper type 1 T cell paradigm and provide evidence for the role of various immune cells in the pathogenesis of experimental autoimmune encephalomyelitis and multiple sclerosis. In this paper we review recent progress and discuss the implications for new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12045717     DOI: 10.1097/00019052-200206000-00001

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  37 in total

1.  IL-7Rα confers susceptibility to experimental autoimmune encephalomyelitis.

Authors:  C C Walline; S Kanakasabai; J J Bright
Journal:  Genes Immun       Date:  2010-09-23       Impact factor: 2.676

2.  Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients.

Authors:  Gloria Dalla Costa; Annamaria Finardi; Livia Garzetti; Tiziana Carandini; Giancarlo Comi; Vittorio Martinelli; Roberto Furlan
Journal:  Neurol Sci       Date:  2017-11-28       Impact factor: 3.307

3.  Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis.

Authors:  Gláucia C Furtado; Maria Cecilia G Marcondes; Jo-Ann Latkowski; Julia Tsai; Allen Wensky; Juan J Lafaille
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

4.  Effect of a Single Bout of Intermittent versus Continuous Walking on Perceptions of Fatigue in People with Multiple Sclerosis.

Authors:  Herb Karpatkin; Adam Rzetelny
Journal:  Int J MS Care       Date:  2012

5.  Loss of Gas6 and Axl signaling results in extensive axonal damage, motor deficits, prolonged neuroinflammation, and less remyelination following cuprizone exposure.

Authors:  Alex K Ray; Juwen C DuBois; Ross C Gruber; Hillary M Guzik; Maria E Gulinello; Geoffrey Perumal; Cedric Raine; Lauren Kozakiewicz; Julie Williamson; Bridget Shafit-Zagardo
Journal:  Glia       Date:  2017-09-19       Impact factor: 7.452

6.  MS14, a Marine Herbal Medicine, an Immunosuppressive Drug in Experimental Autoimmune Encephalomyelitis.

Authors:  Abbas Ebrahimi Kalan; Jafar Soleimani Rad; Laya Kafami; Daryoush Mohamadnezhad; Amir Afshin Khaki; Amaneh Mohammadi Roushandeh
Journal:  Iran Red Crescent Med J       Date:  2014-07-05       Impact factor: 0.611

Review 7.  T-Cells and excitotoxicity: HIV-1 and other neurodegenerative disorders.

Authors:  Muhammad Mukhtar; Edward Acheampong; Zahida Parveen; Roger J Pomerantz
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

8.  Impact of a Demyelination-Inducing Central Nervous System Virus on Expression of Demyelination Genes in Type 2 Lymphoid Cells.

Authors:  Satoshi Hirose; Mihoko Kato; Kati Tormanen; Pedram Shafiei Jahani; Omid Akbari; Homayon Ghiasi
Journal:  J Virol       Date:  2021-01-28       Impact factor: 5.103

9.  Early blood-brain barrier permeability in cerebella of PLSJL mice immunized with myelin basic protein.

Authors:  Sergei Spitsin; Carla Portocarrero; Timothy W Phares; Rhonda B Kean; Christine M Brimer; Hilary Koprowski; D Craig Hooper
Journal:  J Neuroimmunol       Date:  2008-04-11       Impact factor: 3.478

10.  Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis.

Authors:  Chunhe Wang; Yuexin Li; Thomas M Proctor; Arthur A Vandenbark; Halina Offner
Journal:  J Neurosci Res       Date:  2010-01       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.